MarketPulse

schizophrenia treatment

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Neurocrine Advances Nxera's Schizophrenia Drug into Phase 2 with First Patient Dosed

Neurocrine Biosciences doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggering $22.5M milestone payment to partner Nxera Pharma.
NBIXPhase 2 clinical trialdrug discovery
BenzingaBenzinga··Vandana Singh

Teva Advances Monthly Schizophrenia Injection Toward FDA Approval

Teva's once-monthly schizophrenia injection TEV-749 advances toward FDA approval, aiming to improve patient medication compliance and reduce healthcare burden compared to daily oral treatments.
TEVAFDA approvalschizophrenia treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

FDA Accepts Teva's Application for Monthly Olanzapine Injection to Treat Schizophrenia

FDA accepts Teva's application for monthly olanzapine injection treating schizophrenia. The formulation eliminates post-injection monitoring requirements while maintaining efficacy.
TEVAFDA approvalschizophrenia treatment